Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor–positive, HER2-negative breast cancer